SEQUENT

Sequent Scientific Share Price

₹177.29 -4.63 (-2.55%)

19 May, 2025 23:32

SIP TrendupStart SIP in SEQUENT

Start SIP

Performance

  • Low
  • ₹177
  • High
  • ₹182
  • 52 Week Low
  • ₹92
  • 52 Week High
  • ₹241
  • Open Price₹182
  • Previous Close₹182
  • Volume879,530

Investment Returns

  • Over 1 Month + 20.33%
  • Over 3 Month + 19.96%
  • Over 6 Month -5.06%
  • Over 1 Year + 52.11%
SIP Lightning

Smart Investing Starts Here Start SIP with Sequent Scientific for Steady Growth!

Invest Now

Sequent Scientific Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 240.9
  • PEG Ratio
  • 2.1
  • Market Cap Cr
  • 4,438
  • P/B Ratio
  • 6.5
  • Average True Range
  • 8.43
  • EPS
  • 0.51
  • Dividend Yield
  • 0
  • MACD Signal
  • 5.93
  • RSI
  • 67.63
  • MFI
  • 83.48

Sequent Scientific Financials

Sequent Scientific Technicals

EMA & SMA

Current Price
₹177.29
-4.63 (-2.55%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹160.78
  • 50 Day
  • ₹154.61
  • 100 Day
  • ₹157.65
  • 200 Day
  • ₹157.68

Resistance and Support

178.51 Pivot Speed
  • R3 185.72
  • R2 183.72
  • R1 180.51
  • S1 175.30
  • S2 173.30
  • S3 170.09

What's your outlook on Sequent Scientific?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sequent Scientific Ltd. is a leading animal health company in India, specializing in the manufacturing of veterinary pharmaceuticals, including APIs and formulations. It serves global markets with a strong focus on quality, compliance, and innovation.

Sequent Scientific has an operating revenue of Rs. 1,510.87 Cr. on a trailing 12-month basis. An annual revenue de-growth of -3% needs improvement, Pre-tax margin of -4% needs improvement, ROE of -5% is poor and needs improvement. The company has a reasonable debt to equity of 22%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 23% and 7% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 93 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sequent Scientific Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-20 Audited Results & Final Dividend
2025-02-11 Quarterly Results
2024-11-13 Quarterly Results
2024-08-14 Quarterly Results
2024-05-15 Audited Results & Final Dividend
Date Purpose Remarks
2021-09-10 FINAL Rs.0.50 per share(25%)Final Dividend
View More

Sequent Scientific F&O

Sequent Scientific Shareholding Pattern

52.61%
10.22%
6.05%
23.43%
7.69%

About Sequent Scientific

  • NSE Symbol
  • SEQUENT
  • BSE Symbol
  • 512529
  • Managing Director & CEO
  • Mr. Rajaram Narayanan
  • ISIN
  • INE807F01027

Similar Stocks to Sequent Scientific

Sequent Scientific FAQs

Sequent Scientific share price is ₹177 As on 19 May, 2025 | 23:18

The Market Cap of Sequent Scientific is ₹4437.6 Cr As on 19 May, 2025 | 23:18

The P/E ratio of Sequent Scientific is 240.9 As on 19 May, 2025 | 23:18

The PB ratio of Sequent Scientific is 6.5 As on 19 May, 2025 | 23:18

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23